Azurity Pharmaceuticals completed the acquisition of Nextsource Biotechnology.

Azurity Pharmaceuticals, a specialty pharmaceutical company focused on developing complex dosage formulations, completed the acquisition of NextSource Biotechnology, a manufacturer of FDA‑approved oncology, sedation, anesthesia, and pain management products serving both human and animal health markets. Financial terms were not disclosed.